36,649 Shares in AngioDynamics, Inc. (NASDAQ:ANGO) Acquired by Quest Partners LLC

Quest Partners LLC acquired a new stake in AngioDynamics, Inc. (NASDAQ:ANGO) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund acquired 36,649 shares of the medical instruments supplier’s stock, valued at approximately $285,000.

Other institutional investors have also recently modified their holdings of the company. Millennium Management LLC raised its stake in AngioDynamics by 41.9% in the second quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after purchasing an additional 529,861 shares in the last quarter. Western Standard LLC raised its position in shares of AngioDynamics by 878.5% in the 1st quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock valued at $3,072,000 after buying an additional 469,906 shares in the last quarter. First Eagle Investment Management LLC bought a new stake in shares of AngioDynamics during the 2nd quarter worth approximately $1,321,000. Systematic Financial Management LP increased its stake in AngioDynamics by 8.4% in the second quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock valued at $12,763,000 after acquiring an additional 162,972 shares during the last quarter. Finally, Kennedy Capital Management LLC raised its position in AngioDynamics by 425.0% during the first quarter. Kennedy Capital Management LLC now owns 190,236 shares of the medical instruments supplier’s stock valued at $1,117,000 after purchasing an additional 154,002 shares in the last quarter. 89.43% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Canaccord Genuity Group reduced their target price on AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a report on Friday, October 4th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of AngioDynamics in a research note on Friday, October 4th.

Insider Transactions at AngioDynamics

In other AngioDynamics news, CEO James C. Clemmer bought 20,000 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were acquired at an average cost of $6.03 per share, for a total transaction of $120,600.00. Following the transaction, the chief executive officer now directly owns 681,582 shares in the company, valued at approximately $4,109,939.46. This represents a 3.02 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have bought 22,568 shares of company stock worth $135,847. Insiders own 5.40% of the company’s stock.

AngioDynamics Price Performance

Shares of NASDAQ:ANGO opened at $6.99 on Tuesday. AngioDynamics, Inc. has a one year low of $5.26 and a one year high of $8.25. The company has a market cap of $284.03 million, a price-to-earnings ratio of -1.12 and a beta of 0.67. The firm has a 50 day simple moving average of $6.94 and a 200 day simple moving average of $6.80.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.04. AngioDynamics had a negative return on equity of 5.86% and a negative net margin of 83.95%. The company had revenue of $67.50 million for the quarter, compared to the consensus estimate of $67.93 million. During the same quarter last year, the business posted ($0.12) EPS. AngioDynamics’s revenue for the quarter was down 14.2% on a year-over-year basis. As a group, analysts expect that AngioDynamics, Inc. will post -0.41 EPS for the current year.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.